Posts tagged science

Posts tagged science
Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells
In a serendipitous discovery, scientists at The Scripps Research Institute (TSRI) have found a way to turn bone marrow stem cells directly into brain cells.
Current techniques for turning patients’ marrow cells into cells of some other desired type are relatively cumbersome, risky and effectively confined to the lab dish. The new finding points to the possibility of simpler and safer techniques. Cell therapies derived from patients’ own cells are widely expected to be useful in treating spinal cord injuries, strokes and other conditions throughout the body, with little or no risk of immune rejection.
“These results highlight the potential of antibodies as versatile manipulators of cellular functions,” said Richard A. Lerner, the Lita Annenberg Hazen Professor of Immunochemistry and institute professor in the Department of Cell and Molecular Biology at TSRI, and principal investigator for the new study. “This is a far cry from the way antibodies used to be thought of—as molecules that were selected simply for binding and not function.”
The researchers discovered the method, reported in the online Early Edition of the Proceedings of the National Academy of Sciences the week of April 22, 2013, while looking for lab-grown antibodies that can activate a growth-stimulating receptor on marrow cells. One antibody turned out to activate the receptor in a way that induces marrow stem cells—which normally develop into white blood cells—to become neural progenitor cells, a type of almost-mature brain cell.
Nature’s Toolkit
Natural antibodies are large, Y-shaped proteins produced by immune cells. Collectively, they are diverse enough to recognize about 100 billion distinct shapes on viruses, bacteria and other targets. Since the 1980s, molecular biologists have known how to produce antibodies in cell cultures in the laboratory. That has allowed them to start using this vast, target-gripping toolkit to make scientific probes, as well as diagnostics and therapies for cancer, arthritis, transplant rejection, viral infections and other diseases.
In the late 1980s, Lerner and his TSRI colleagues helped invent the first techniques for generating large “libraries” of distinct antibodies and swiftly determining which of these could bind to a desired target. The anti-inflammatory antibody Humira®, now one of the world’s top-selling drugs, was discovered with the benefit of this technology.
Last year, in a study spearheaded by TSRI Research Associate Hongkai Zhang, Lerner’s laboratory devised a new antibody-discovery technique—in which antibodies are produced in mammalian cells along with receptors or other target molecules of interest. The technique enables researchers to determine rapidly not just which antibodies in a library bind to a given receptor, for example, but also which ones activate the receptor and thereby alter cell function.
Lab Dish in a Cell
For the new study, Lerner laboratory Research Associate Jia Xie and colleagues modified the new technique so that antibody proteins produced in a given cell are physically anchored to the cell’s outer membrane, near its target receptors. “Confining an antibody’s activity to the cell in which it is produced effectively allows us to use larger antibody libraries and to screen these antibodies more quickly for a specific activity,” said Xie. With the improved technique, scientists can sift through a library of tens of millions of antibodies in a few days.
In an early test, Xie used the new method to screen for antibodies that could activate the GCSF receptor, a growth-factor receptor found on bone marrow cells and other cell types. GCSF-mimicking drugs were among the first biotech bestsellers because of their ability to stimulate white blood cell growth—which counteracts the marrow-suppressing side effect of cancer chemotherapy.
The team soon isolated one antibody type or “clone” that could activate the GCSF receptor and stimulate growth in test cells. The researchers then tested an unanchored, soluble version of this antibody on cultures of bone marrow stem cells from human volunteers. Whereas the GCSF protein, as expected, stimulated such stem cells to proliferate and start maturing towards adult white blood cells, the GCSF-mimicking antibody had a markedly different effect.
“The cells proliferated, but also started becoming long and thin and attaching to the bottom of the dish,” remembered Xie.
To Lerner, the cells were reminiscent of neural progenitor cells—which further tests for neural cell markers confirmed they were.
A New Direction
Changing cells of marrow lineage into cells of neural lineage—a direct identity switch termed “transdifferentiation”—just by activating a single receptor is a noteworthy achievement. Scientists do have methods for turning marrow stem cells into other adult cell types, but these methods typically require a radical and risky deprogramming of marrow cells to an embryonic-like stem-cell state, followed by a complex series of molecular nudges toward a given adult cell fate. Relatively few laboratories have reported direct transdifferentiation techniques.
“As far as I know, no one has ever achieved transdifferentiation by using a single protein—a protein that potentially could be used as a therapeutic,” said Lerner.
Current cell-therapy methods typically assume that a patient’s cells will be harvested, then reprogrammed and multiplied in a lab dish before being re-introduced into the patient. In principle, according to Lerner, an antibody such as the one they have discovered could be injected directly into the bloodstream of a sick patient. From the bloodstream it would find its way to the marrow, and, for example, convert some marrow stem cells into neural progenitor cells. “Those neural progenitors would infiltrate the brain, find areas of damage and help repair them,” he said.
While the researchers still aren’t sure why the new antibody has such an odd effect on the GCSF receptor, they suspect it binds the receptor for longer than the natural GCSF protein can achieve, and this lengthier interaction alters the receptor’s signaling pattern. Drug-development researchers are increasingly recognizing that subtle differences in the way a cell-surface receptor is bound and activated can result in very different biological effects. That adds complexity to their task, but in principle expands the scope of what they can achieve. “If you can use the same receptor in different ways, then the potential of the genome is bigger,” said Lerner.

Putting the brakes on Parkinson’s
The earliest signs of Parkinson’s disease can be deceptively mild. The first thing that movie star Michael J. Fox noticed was twitching of the little finger of his left hand. For years, he made light of the apparently harmless tic. But such tremors typically spread, while muscles stiffen up and directed movements take longer to carry out. Research groups led by Armin Giese of LMU Munich and Christian Griesinger at the Max Planck Institute for Biophysical Chemistry in Göttingen have developed a chemical compound that slows down the onset and progression of Parkinson’s disease in mice. The scientists hope that this approach will give them a way to treat the cause of Parkinson’s and so arrest its progress.
The disease usually becomes manifest between the ages of 50 and 60, and results from the loss of dopamine-producing nerve cells in the substantia nigra, which is part of the midbrain. Under the microscope, the affected cells are seen to contain insoluble precipitates made up of a protein called alpha-synuclein. As an early step in the pathological cascade, this protein forms so-called oligomers, tiny aggregates consisting of small numbers of alpha-synuclein molecules, which are apparently highly neurotoxic. By the time the first overt symptoms appear in humans, more than half of the vulnerable cells have already been lost. Many researchers therefore focus on developing methods for early diagnosis of the condition. However, current therapies only alleviate symptoms, so the research teams led by Armin Giese and Christian Griesinger set out to address the underlying cause of nerve-cell death.
Together, the scientists have developed a substance which, in mouse models of the disease, reduces the rate of growth of the protein deposits and delays nerve cell degeneration to a yet unprecedented degree. As a consequence, mice treated with this agent remain disease-free for longer than non-medicated controls. “The most striking feature of the new compound is that it is the first that directly targets oligomers and interferes with their formation,” explains Christian Griesinger, head of the Department of NMR-based Structural Biology and Director at the Max Planck Institute for Biophysical Chemistry. The discovery is the result of years of hard work. “Combining skills from a range of disciplines has been the key to our success. Biologists, chemists, clinicians, physicists, and veterinarians have all contributed to the development of the therapeutic compound,” adds Armin Giese, who leads a research group at LMU’s Center for Neuropathology and Prion Research.
Giese and his colleagues systematically tested 20,000 candidate substances for the ability to block formation of the protein deposits that are typical for the disease. The screen made use of an extremely sensitive laser-based assay developed by Giese years ago when he was working together with Nobel Laureate Manfred Eigen at the Max Planck Institute for Biophysical Chemistry in Göttingen. Some interesting lead compounds identified during the very first phase of the screening program served as starting point for further optimization. Ultimately, one substance proved to be particularly active. Andrei Leonov a chemist in Griesinger’s team, finally succeeded in synthesizing a pharmaceutically promising derivative. This is well tolerated at dosage levels with significant therapeutic effects, can be administered with the food, and penetrates the blood-brain barrier, reaching high levels in the brain. The two teams have already applied for a patent on the compound which they called Anle138b – an abbreviation of Andrei Leonov’s first name and surname.
A complex series of experiments has provided encouraging indications that Anle138b could also be of therapeutic use in humans. These tests involved not only biochemical and structural investigations of Anle138b’s mode of action but also employed several animal models of Parkinson’s which are under study in Munich and in laboratories of the Excellence Cluster “Nanoscale Microscopy and Molecular Physiology of the Brain” in Göttingen. Mice exposed to Anle138b were found to display better motor coordination than their untreated siblings. “We use a kind of fitness test to evaluate muscle coordination,” Giese explains. “The mice are placed on a rotating rod and we measure how long the animals can keep their balance.”
Generally speaking, the earlier the onset of treatment, the longer the animals remained disease free. What’s more, the beneficial effects of Anle138b are not restricted to animals with Parkinson’s disease. “Creutzfeldt-Jakob disease is caused by toxic aggregates of the prion protein,” Griesinger points out. “And here too, Anle138b effectively inhibits clumping and significantly increases survival times.” These findings hint that Anle138b might also prevent the formation of insoluble deposits formed by other proteins, such as the tau protein that is associated with Alzheimer’s disease. Further experiments will address this issue. Anle138b will therefore be a useful research tool in medicine, as it will enable scientists to study the process of oligomer formation in the test-tube and to determine how their assembly is inhibited. The researchers hope ultimately to gain new insights into the mechanisms into how neurodegenerative disorders develop.
The drugs so far available for treatment of Parkinson’s disease only control its symptoms by enhancing the function of the surviving nerve cells in the substantia nigra. “With Anle138b, we may have the first representative of a new class of neuroprotective agents allowing to retard or even halt the progression of conditions such as Parkinson’s or Creutzfeldt-Jakob disease,” Griesinger says. However, he warns that the findings in mice cannot immediately be applied to humans. The next step will be to carry out toxicity tests in non-rodent species. Only if these are successful will clinical trials in patients become a realistic possibility. As clinician Giese emphasizes: “To successfully establish a novel therapeutic agent for treatment of real patients is a laborious task that requires a lot of work as well as serendipity.”
Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson’s disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain. Parkinson’s is a devastating neurodegenerative disorder caused by the death of dopamine neurons in a key motor area of the brain, the substantia nigra (SN). Loss of these neurons leads to the characteristic tremor and slowed movements of PD, which get increasingly worse with time. Currently, more than 1% of the population over age 60 has PD and approximately 60,000 Americans are newly diagnosed every year. The available drugs on the market for PD mimic or replace the lost dopamine but do not get to the heart of the problem, which is the progressive loss of the dopamine neurons.
The focus of Dr. Barbara Waszczak’s lab at Northeastern University in Boston is to find a way to harvest the potential of glial cell line-derived neurotrophic factor (GDNF) as a treatment for PD. GDNF is a protein known to nourish dopamine neurons by activating survival and growth-promoting pathways inside the cells. Not surprisingly, GDNF is able to protect dopamine neurons from injury and restore the function of damaged and dying neurons in many animal models of PD. However, the action of GDNF is limited by its inability to cross the blood-brain barrier (BBB), thus requiring direct surgical injection into the brain. To circumvent this problem, Waszczak’s lab is investigating intranasal delivery as a way to bypass the BBB. Their previous work showed that intranasal delivery of GDNF protects dopamine neurons from damage by the neurotoxin, 6-hydroxydopamine (6-OHDA), a standard rat model of PD.
Taking this work a step further, Brendan Harmon, working in Waszczak’s lab, has adapted the intranasal approach so that cells in the brain can continuously produce GDNF. His work utilized nanoparticles, developed by Copernicus Therapeutics, Inc., which are able to transfect brain cells with an expression plasmid carrying the gene for GDNF (pGDNF). When given intranasally to rats, these pGDNF nanoparticles increase GDNF production throughout the brain for long periods, avoiding the need for frequent re-dosing. Now, in new research presented on April 20 at 12:30 pm during Experimental Biology 2013 in Boston, MA, Harmon reports that intranasal administration of Copernicus’ pGDNF nanoparticles results in GDNF expression sufficient to protect SN dopamine neurons in the 6-OHDA model of PD.
Waszczak and Harmon believe that intranasal delivery of Copernicus’ nanoparticles may provide an effective and non-invasive means of GDNF gene therapy for PD, and an avenue for transporting other gene therapy vectors to the brain. This work, which was funded in part by the Michael J. Fox Foundation for Parkinson’s Research and Northeastern University, has the potential to greatly expand treatment options for PD and many other central nervous system disorders.
(Source: eurekalert.org)
CI Therapy Produces Increase in Grey Matter in Brains of Children with Cerebral Palsy
Researchers at the University of Alabama at Birmingham (UAB) report that children with cerebral palsy who underwent Constraint Induced Movement therapy (CI therapy) saw a significant increase in grey matter volume in areas of the brain associated with movement. The findings, published online April 22, 2013 in Pediatrics, are the first to show that structural remodeling of the brain occurs during rehabilitation in a pediatric population.
“It is well understood that CI therapy produces a re-wiring of the brain, leading to functional improvement in motor skills in children and adults who have experienced a brain injury,” said Edward Taub, Ph.D., the developer of CI therapy and a study co-author. “This study reinforces the idea that CI therapy also remodels the brain, producing a real, physical change in the brain.”
Grey matter is a component of the central nervous system, consisting primarily of neuronal cell bodies, glial cells and dendrites. The study examined ten children with cerebral palsy, between the ages of 2 and 7, who underwent a three week course of CI therapy. Changes in grey matter were assessed with a technique called voxel-based morphometry (VBM), performed on images acquired through magnetic resonance imaging.
“We saw increases in grey matter volume in the sensorimotor cortices on both sides of the brain and in the hippocampus,” said Chelsey Sterling, M.A., a graduate student in medical psychology and first author of the study. “These increases were accompanied by large improvements in spontaneous arm use in the home environment. Notably, increases in grey matter correlated with improvement in motor activity.”
Sterling says the significant correlation between increases in grey matter volume and magnitude of motor improvement raises the possibility of a causal relationship.
The researchers suggest the observed increase in grey matter could be due to one or more different processes, including an increase in synaptic density, the creation of new neurons or glial cells or the establishment of new blood vessels within the brain.
“An increase in grey matter is indicative that the brain is capable of supporting increased motor activity and function,” said Gitendra Uswatte, Ph.D., a study co-author. “Along with the improvements observed in the dexterity and everyday use of the arm that was the target of rehabilitation, this is a strong indication that a child with cerebral palsy can have substantial gains in motor function when provided with the correct stimulation.”
VBM analysis was performed three weeks prior to therapy, at the beginning of therapy and at the end of the three week therapy period. The authors say that no significant grey matter change was seen during the three weeks before treatment.
The children underwent intensive motor training for three hours each weekday for a three week period in which the child’s less-affected arm was continuously restrained in a long arm cast. Each child’s caregiver received a transfer package, which included steps to induce continuation of use of the more-affected arm at home. The MRI scans were performed at Children’s of Alabama.
Taub, a university professor in the Department of Psychology, developed the family of techniques called CI therapy. The therapy has been shown to be effective in improving the rehabilitation of movement after stroke and other neurological injuries in both children and adults.
“The motor improvement and changes in grey matter following CI therapy observed in this study are similar to those observed previously in adults,” said Taub. “It is further evidence that the brain has a remarkable capacity to heal itself when presented with an efficacious rehabilitation intervention such as CI therapy.”
For the first time, human embryonic stem cells have been transformed into nerve cells that helped mice regain the ability to learn and remember.
A study at UW-Madison is the first to show that human stem cells can successfully implant themselves in the brain and then heal neurological deficits, says senior author Su-Chun Zhang, a professor of neuroscience and neurology.
Once inside the mouse brain, the implanted stem cells formed two common, vital types of neurons, which communicate with the chemicals GABA or acetylcholine. “These two neuron types are involved in many kinds of human behavior, emotions, learning, memory, addiction and many other psychiatric issues,” says Zhang.
The human embryonic stem cells were cultured in the lab, using chemicals that are known to promote development into nerve cells — a field that Zhang has helped pioneer for 15 years. The mice were a special strain that do not reject transplants from other species.
After the transplant, the mice scored significantly better on common tests of learning and memory in mice. For example, they were more adept in the water maze test, which challenged them to remember the location of a hidden platform in a pool.
The study began with deliberate damage to a part of the brain that is involved in learning and memory.
Three measures were critical to success, says Zhang: location, timing and purity. “Developing brain cells get their signals from the tissue that they reside in, and the location in the brain we chose directed these cells to form both GABA and cholinergic neurons.”
The initial destruction was in an area called the medial septum, which connects to the hippocampus by GABA and cholinergic neurons. “This circuitry is fundamental to our ability to learn and remember,” says Zhang.
The transplanted cells, however, were placed in the hippocampus — a vital memory center — at the other end of those memory circuits. After the transferred cells were implanted, in response to chemical directions from the brain, they started to specialize and connect to the appropriate cells in the hippocampus.
The process is akin to removing a section of telephone cable, Zhang says. If you can find the correct route, you could wire the replacement from either end.
For the study, published in the current issue of Nature Biotechnology, Zhang and first author Yan Liu, a postdoctoral associate at the Waisman Center on campus, chemically directed the human embryonic stem cells to begin differentiation into neural cells, and then injected those intermediate cells. Ushering the cells through partial specialization prevented the formation of unwanted cell types in the mice.
Ensuring that nearly all of the transplanted cells became neural cells was critical, Zhang says. “That means you are able to predict what the progeny will be, and for any future use in therapy, you reduce the chance of injecting stem cells that could form tumors. In many other transplant experiments, injecting early progenitor cells resulted in masses of cells — tumors. This didn’t happen in our case because the transplanted cells are pure and committed to a particular fate so that they do not generate anything else. We need to be sure we do not inject the seeds of cancer.”
Brain repair through cell replacement is a Holy Grail of stem cell transplant, and the two cell types are both critical to brain function, Zhang says. “Cholinergic neurons are involved in Alzheimer’s and Down syndrome, but GABA neurons are involved in many additional disorders, including schizophrenia, epilepsy, depression and addiction.”
Though tantalizing, stem-cell therapy is unlikely to be the immediate benefit. Zhang notes that “for many psychiatric disorders, you don’t know which part of the brain has gone wrong.” The new study, he says, is more likely to see immediate application in creating models for drug screening and discovery.
(Source: news.wisc.edu)
A contact lens on the bathroom floor, an escaped hamster in the backyard, a car key in a bed of gravel: How are we able to focus so sharply to find that proverbial needle in a haystack? Scientists at the University of California, Berkeley, have discovered that when we embark on a targeted search, various visual and non-visual regions of the brain mobilize to track down a person, animal or thing.

That means that if we’re looking for a youngster lost in a crowd, the brain areas usually dedicated to recognizing other objects such as animals, or even the areas governing abstract thought, shift their focus and join the search party. Thus, the brain rapidly switches into a highly focused child-finder, and redirects resources it uses for other mental tasks.
“Our results show that our brains are much more dynamic than previously thought, rapidly reallocating resources based on behavioral demands, and optimizing our performance by increasing the precision with which we can perform relevant tasks,” said Tolga Cukur, a postdoctoral researcher in neuroscience at UC Berkeley and lead author of the study published today (Sunday April 21) in the journal Nature Neuroscience.
“As you plan your day at work, for example, more of the brain is devoted to processing time, tasks, goals and rewards, and as you search for your cat, more of the brain becomes involved in recognition of animals,” he added.
The findings help explain why we find it difficult to concentrate on more than one task at a time. The results also shed light on how people are able to shift their attention to challenging tasks, and may provide greater insight into neurobehavioral and attention deficit disorders such as ADHD.
These results were obtained in studies that used functional Magnetic Resonance Imaging (fMRI) to record the brain activity of study participants as they searched for people or vehicles in movie clips. In one experiment, participants held down a button whenever a person appeared in the movie. In another, they did the same with vehicles.
The brain scans simultaneously measured neural activity via blood flow in thousands of locations across the brain. Researchers used regularized linear regression analysis, which finds correlations in data, to build models showing how each of the roughly 50,000 locations near the cortex responded to each of the 935 categories of objects and actions seen in the movie clips. Next, they compared how much of the cortex was devoted to detecting humans or vehicles depending on whether or not each of those categories was the search target.

They found that when participants searched for humans, relatively more of the cortex was devoted to humans, and when they searched for vehicles, more of the cortex was devoted to vehicles. For example, areas that were normally involved in recognizing specific visual categories such as plants or buildings switched to become attuned to humans or vehicles, vastly expanding the area of the brain engaged in the search.
“These changes occur across many brain regions, not only those devoted to vision. In fact, the largest changes are seen in the prefrontal cortex, which is usually thought to be involved in abstract thought, long-term planning, and other complex mental tasks,” Cukur said.
The findings build on an earlier UC Berkeley brain imaging study that showed how the brain organizes thousands of animate and inanimate objects into what researchers call a “continuous semantic space.” Those findings challenged previous assumptions that every visual category is represented in a separate region of the visual cortex. Instead, researchers found that categories are actually represented in highly organized, continuous maps.
The latest study goes further to show how the brain’s semantic space is warped during a visual search, depending on the search target. Researchers have posted their results in an interactive, online brain viewer. Other co-authors of the study are UC Berkeley neuroscientists Jack Gallant, Alexander Huth and Shinji Nishimoto. Funding for the research was provided by the National Eye Institute of the National Institutes of Health.
When the brains of those who have succumbed to age-related neurodegeneration are analyzed post-mortem, they typically show significant atrophy on all scales. Not only is the cortex thinner and sparser, but the hollow ventricles inside the brain are grossly enlarged. In the absence of any specific disease, these general trends are still familiar. It has traditionally been assumed that the dynamic microfeatures of aged brains—the growth of the fine neurites and the synapses they make—would similarly be degenerate. In other words, synaptic growth would have either entered some form of stasis, or alternatively, a state of permanent decay with replacement by matrix or scar tissue. Contrary to these expectations, recent research shows increased structural plasticity in the axonal component of synapses in the aged mouse cortex. Reporting in the current issues of PNAS, researchers provide evidence that the observed behavioral deficits in these animals may be due to an inability to maintain persistent synaptic structure, rather than because of a loss of plasticity.

Specifically, the researchers found dramatic increases in the rates of synapse formation and elimination. They used two-photon microscopy to image axonal arbors and boutons in aged brains over time. Compared to young adult brains, established synaptic boutons in aged brain showed 10-fold higher rates of destabilization, and 20-fold higher turnover. The researchers also demonstrated, that while the size and density of synapses was comparable, size fluctuations were significantly higher in the aged brains.
Changes in synaptic structure are believed to be the mechanism for encoding long-term memory in the brain. In the absence of the full molecular picture underlying the way they change and grow, macroscopic appearance (size) is a convenient stand-in used to gauge relative importance of a particular synapse. Among other things, a larger synapse has greater resource at its disposal to reliably match incoming spikes to transmitter release. Not only can a larger synapse generally do this matching faster, they can do it for a longer time. The new studies suggest, however, that decreased ability to form new memories, or learn new behaviors, results from synapses being too fickle, rather than from loss of flexibility.
Clearly the full behavior of synapses is far from understood, despite it being one of the central preoccupations of experimental neuroscience. It is generally believed that the average synapse is at best able to match an incoming spike with fusion of a vesicle (and subsequent transmitter release) roughly half of the time. Many theoretical efforts have been made to account for this fact. One approach has been to do a strict accounting analysis of the energetic use of ATP by a neuron’s entire signalling tree. In other words, estimate how a neuron partitions its ATP budget between transmitting information in the form of spikes down the axon, and that spent in completing the hand-off to the next neuron at the synapse.
Detailed and painstaking measurements of axonal structural dynamics, as done here by the authors, is critical ground-floor work towards understand neural circuits. Isolated molecular details, while important, will never be sufficient to completely understand how learning and memory emerge from architectural changes. The current efforts of the BRAIN Initiative to map the complete connectome of a brain, together with a full activity map, will also need to include efforts to create what might be called, a theory of neurons. The ways in which neurons budget their energy, is likely to a central component of such a theory.
As a start, one postulate of a theory of neurons, that is consistent with the one-half probability for synaptic information transfer, might be the following: neurons tend to match the energy spent in sending spikes through their entire axonal arbor, with the sum total of the energy spent at all terminal boutons of that axon. The temporal aspects of how synapses are generated and eliminated in a short-lived animal, like a mouse, may be far different than those in a human. Understanding how these processes change with age, and with the amount of energy available to synapses to effect that change, will help complete the larger picture.
(Source: medicalxpress.com)
How a movie changed one man’s vision forever
Bruce Bridgeman lived with a flat view of the world, until a trip to the cinema unexpectedly rewired his brain to see the world in 3D. The question is how it happened.
On 16 February 2012, Bridgeman went to the theatre with his wife to see Martin Scorsese’s 3D family adventure. Like everyone else, he paid a surcharge for a pair of glasses, despite thinking they would be a complete waste of money. Bridgeman, a 67-year-old neuroscientist at the University of California in Santa Cruz, grew up nearly stereoblind, that is, without true perception of depth. “When we’d go out and people would look up and start discussing some bird in the tree, I would still be looking for the bird when they were finished,” he says. “For everybody else, the bird jumped out. But to me, it was just part of the background.”
All that changed when the lights went down and the previews finished. Almost as soon as he began to watch the film, the characters leapt from the screen in a way he had never experienced. “It was just literally like a whole new dimension of sight. Exciting,” says Bridgeman.
But this wasn’t just movie magic. When he stepped out of the cinema, the world looked different. For the first time, Bridgeman saw a lamppost standing out from the background. Trees, cars and people looked more alive and more vivid than ever. And, remarkably, he’s seen the world in 3D ever since that day. “Riding to work on my bike, I look into a forest beside the road and see a riot of depth, every tree standing out from all the others,” he says. Something had happened. Some part of his brain had awakened.
Conventional wisdom says that what happened to Bridgeman is impossible. Like many of the 5-10% of the population living with stereoblindness, he was resigned to seeing a world without depth. What Bridgeman experienced in the theatre has been observed in clinics previously – the most famous case being Sue Barry, or “Stereo Sue”, who according to the author and neurologist Oliver Sacks first experienced stereovision while she was undergoing vision therapy. Her visual epiphany came during the course of professional therapy in her late-forties. The question is why after several decades of living in a flat, two-dimensional world did Bridgeman’s brain spontaneously begin to process 3D images?
(Credit: swsmh)
Up to 10 per cent of the population are affected by specific learning disabilities (SLDs), such as dyslexia, dyscalculia and autism, translating to 2 or 3 pupils in every classroom according to a new study.
The study – by academics at UCL and Goldsmiths - also indicates that children are frequently affected by more than one learning disability.
The research, published in Science, helps to clarify the underlying causes of learning disabilities and the best way to tailor individual teaching and learning for affected individuals and education professionals.
Specific learning disabilities arise from atypical brain development with complicated genetic and environmental causes, causing such conditions as dyslexia, dyscalculia, attention-deficit/hyperactivity disorder, autism spectrum disorder and specific language impairment.
While these conditions in isolation already provide a challenge for educators, an additional problem is that specific learning disabilities also co-occur for more often that would be expected. As, for example, in children with attention-deficit/hyperactivity disorder, 33 to 45 per cent also suffer from dyslexia and 11 per cent from dyscalculia.
Lead author Professor Brian Butterworth (UCL Institute of Cognitive Neuroscience) said: “We now know that there are many disorders of neurological development that can give rise to learning disabilities, even in children of normal or even high intelligence, and that crucially these disabilities can also co-occur far more often that you’d expect based on their prevalence.
"We are also finally beginning to find effective ways to help learners with one or more SLDs, and although the majority of learners can usually adapt to the one-size-fits-all approach of whole class teaching, those with SLDs will need specialised support tailored to their unique combination of disabilities."
As part of the study, Professor Butterworth and Dr Yulia Kovas (Goldsmiths) have summarised what is currently known about SLD’s neural and genetic basis to help clarify what is causing these disabilities to develop, helping to improve teaching for individual learners, and also training for school psychologists, clinicians and teachers.
What the team hope is that by developing an understanding of how individual differences in brain development interact with formal education, and also adapting learning pathways to individual needs, those with specific learning disabilities will produce more tailored education for such learners.
Professor Butterworth said: “Each child has a unique cognitive and genetic profile, and the educational system should be able to monitor and adapt to the learner’s current repertoire of skills and knowledge.
"A promising approach involves the development of technology-enhanced learning applications – such as games - that are capable of adapting to individual needs for each of the basic disciplines."
(Source: eurekalert.org)
People with genes that make it tough for them to engage socially with others seem to be better than average at hypnotizing themselves. A study published today in Psychoneuroendocrinology concludes that such individuals are particularly good at becoming absorbed in their own internal world, and might also be more susceptible to other distortions of reality.

Psychologist Richard Bryant of the University of New South Wales in Sydney and his colleagues tested the hypnotizability of volunteers with different forms of the receptor for oxytocin, a hormone that increases trust and social bonding. (Oxytocin’s association with emotional attachment also earned it the nickname of ‘love hormone’.) Those with gene variants linked to social detachment and autism were found to be most susceptible to hypnosis.
Hypnosis has intrigued scientists since the nineteenth-century physician James Braid used it to alleviate pain in a variety of medical conditions, but it has never been fully understood. Hypnotized people can undergo a range of unusual experiences, including amnesia, anaesthesia and the loss of the ability to move their limbs. But some individuals are more affected by hypnosis than others — and no one knows why.
Hormones and hypnotism
How susceptible someone is to persuasion is an important factor in how easily they can be hypnotized by someone else. Bryant and his colleagues have previously shown that spraying a shot of oxytocin up people’s noses makes them more hypnotizable, and more likely to engage in potentially embarrassing activities such as swearing or dancing at a hypnotist’s suggestion.
When it comes to self-hypnosis, however, the team wondered whether people who can easily disengage from the external world and become lost in their own imagination might do better. In their latest study, they asked 185 volunteers to hypnotize themselves with the aid of an audio recording, then assessed the depth of their hypnosis using checks such as whether they were unable to open their eyes, or could hallucinate a sound.
The researchers used a questionnaire to test the participants’ ability to become absorbed in internal and imagined experiences, and tested them for variants of the oxytocin-receptor gene at two places in the gene sequence — rs53576 and rs2254298 — that that increase the risk of social detachment and autism. Participants with these variants scored highest for hypnotizability and absorption.
Bryant suggests that as well as being more hypnotizable, such individuals might “be influenced to have a range of experiences that more reality-based people cannot”. For example, this capacity might help to explain why some people respond better to placebos, or are more likely to accept paranormal or religious experiences.
“At this point we do not know anything about genetic bases of suggestibility per se,” says Bryant. “The current finding does provide some direction for exploring this.”
Aleksandr Kogan of the University of Cambridge, UK, who works on the genetics of social psychology, says that the results fit well with what is known about the oxytocin-receptor gene, particularly for variants at site rs53576. Among white people, these influence an individual’s sensitivity to social cues, he says. “That this would reflect a difference in internal experiences makes sense.”
(Source: nature.com)